首页> 外文期刊>British Journal of Haematology >Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood.
【24h】

Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood.

机译:模仿造血生境微环境为从脐带血扩增造血和巨核祖细胞提供了一种新的策略。

获取原文
获取原文并翻译 | 示例
           

摘要

Severe neutropenia and protracted thrombocytopenia remain serious clinical problems following cord blood transplantation (CBT) due to the paucity of stem and progenitor cells in the grafts. Administration of ex-vivo expanded megakaryocyte progenitor cells may facilitate platelet production. We propose a novel strategy to expand these rare cells ex-vivo, from a small portion of the cord blood (CB) unit, using fibronectin (FN), a major component of hematopoietic niches, combined with cytokines, including thrombopoietin and the hematopoietic stress-associated acetylcholinesterase readthrough peptide (ARP). Application of multiple gates and high definition flow cytometry enabled clear resolution of expanded hematopoietic stem/precursor cells (HSPC) and megakaryocyte progenitors (Mk-p) and their early subsets while eliminating positively stained non-relevant cells. FN increased viability, expansion of all CD34(+) HSPC populations and Mk-p. The combination of FN + thrombopoietin + ARP maintained and expanded very early myeloid and thrombopoietic precursors, increased the proliferation of megakaryocyte, granulocyte-macrophage and multilineage colony-forming progenitors and supported Mk maturation as measured by ploidy and glycoprotein IIb/IIIa expression by quantiative reverse transcription polymerase chain reaction. This approach, which involves expanding HSPC and Mk precursors from a small portion of the CB unit, without sacrificing the coveted stem cells, may lead to improved cell therapy modalities to facilitate earlier myelopoiesis and platelet production post-CBT.
机译:脐血移植(CBT)后,由于移植物中干细胞和祖细胞的缺乏,严重的中性粒细胞减少症和血小板减少症仍然是严重的临床问题。离体扩增的巨核细胞祖细胞的给药可以促进血小板的产生。我们提出了一种新颖的策略,使用纤连蛋白(FN)(造血生境的主要成分)结合细胞因子(包括血小板生成素和造血应激),从一小部分脐血(CB)单元中体外扩增这些稀有细胞。相关的乙酰胆碱酯酶通读肽(ARP)。多门和高清晰度流式细胞仪的应用可以清楚地分辨扩增的造血干/前体细胞(HSPC)和巨核祖细胞(Mk-p)及其早期亚群,同时消除了阳性染色的无关细胞。 FN增加了生存力,扩大了所有CD34(+)HSPC种群和Mk-p。 FN +血小板生成素+ ARP的组合保持并扩展了非常早期的髓样和血小板生成前体,增加了巨核细胞,粒细胞巨噬细胞和多谱系集落祖细胞的增殖,并通过倍性和糖蛋白IIb / IIIa表达(通过定量反向测定)支持了Mk成熟转录聚合酶链反应。这种方法涉及从CB单元的一小部分扩展HSPC和Mk前体,而不牺牲梦the以求的干细胞,可能会导致细胞治疗方法得到改善,以促进CBT后的早期骨髓生成和血小板生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号